vs

Side-by-side financial comparison of HAWTHORN BANCSHARES, INC. (HWBK) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $21.2M, roughly 1.7× HAWTHORN BANCSHARES, INC.). On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 12.2%). HAWTHORN BANCSHARES, INC. produced more free cash flow last quarter ($22.8M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 9.1%).

Hawthorn Bancshares, Inc. is a U.S. regional bank holding company operating through its wholly owned subsidiary Hawthorn Bank. It provides a full range of retail and commercial banking services including deposit products, mortgage loans, small business financing, commercial lending, and wealth management solutions, primarily serving individual customers and small to mid-sized enterprises across local communities in Missouri.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

HWBK vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.7× larger
RXRX
$35.5M
$21.2M
HWBK
Growing faster (revenue YoY)
RXRX
RXRX
+669.6% gap
RXRX
681.7%
12.2%
HWBK
More free cash flow
HWBK
HWBK
$70.2M more FCF
HWBK
$22.8M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
9.1%
HWBK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HWBK
HWBK
RXRX
RXRX
Revenue
$21.2M
$35.5M
Net Profit
$-108.1M
Gross Margin
59.8%
Operating Margin
35.7%
-304.8%
Net Margin
-304.2%
Revenue YoY
12.2%
681.7%
Net Profit YoY
39.6%
EPS (diluted)
$0.90
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HWBK
HWBK
RXRX
RXRX
Q4 25
$21.2M
$35.5M
Q3 25
$20.6M
$5.2M
Q2 25
$19.7M
$19.2M
Q1 25
$18.8M
$14.7M
Q4 24
$18.9M
$4.5M
Q3 24
$18.1M
$26.1M
Q2 24
$18.2M
$14.4M
Q1 24
$17.8M
$13.8M
Net Profit
HWBK
HWBK
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$6.1M
$-162.3M
Q2 25
$6.1M
$-171.9M
Q1 25
$5.4M
$-202.5M
Q4 24
$-178.9M
Q3 24
$4.6M
$-95.8M
Q2 24
$4.6M
$-97.5M
Q1 24
$4.5M
$-91.4M
Gross Margin
HWBK
HWBK
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
HWBK
HWBK
RXRX
RXRX
Q4 25
35.7%
-304.8%
Q3 25
36.4%
-3327.6%
Q2 25
37.9%
-916.8%
Q1 25
35.2%
-1297.9%
Q4 24
29.9%
-4042.4%
Q3 24
31.1%
-377.1%
Q2 24
31.2%
-697.4%
Q1 24
30.5%
-698.4%
Net Margin
HWBK
HWBK
RXRX
RXRX
Q4 25
-304.2%
Q3 25
29.8%
-3135.3%
Q2 25
31.0%
-894.2%
Q1 25
28.7%
-1373.3%
Q4 24
-3935.5%
Q3 24
25.3%
-367.5%
Q2 24
25.5%
-676.6%
Q1 24
25.1%
-662.4%
EPS (diluted)
HWBK
HWBK
RXRX
RXRX
Q4 25
$0.90
$-0.17
Q3 25
$0.88
$-0.36
Q2 25
$0.88
$-0.41
Q1 25
$0.77
$-0.50
Q4 24
$0.66
$-0.56
Q3 24
$0.66
$-0.34
Q2 24
$0.66
$-0.40
Q1 24
$0.63
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HWBK
HWBK
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$104.3M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$174.2M
$1.1B
Total Assets
$1.9B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HWBK
HWBK
RXRX
RXRX
Q4 25
$104.3M
$743.3M
Q3 25
$99.9M
$659.8M
Q2 25
$100.3M
$525.1M
Q1 25
$102.3M
$500.5M
Q4 24
$51.0M
$594.4M
Q3 24
$54.2M
$427.6M
Q2 24
$75.8M
$474.3M
Q1 24
$43.5M
$296.3M
Total Debt
HWBK
HWBK
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
HWBK
HWBK
RXRX
RXRX
Q4 25
$174.2M
$1.1B
Q3 25
$164.9M
$1.0B
Q2 25
$156.8M
$919.1M
Q1 25
$153.4M
$933.9M
Q4 24
$149.5M
$1.0B
Q3 24
$146.5M
$524.6M
Q2 24
$138.2M
$584.4M
Q1 24
$136.6M
$401.2M
Total Assets
HWBK
HWBK
RXRX
RXRX
Q4 25
$1.9B
$1.5B
Q3 25
$1.9B
$1.4B
Q2 25
$1.9B
$1.3B
Q1 25
$1.9B
$1.3B
Q4 24
$1.8B
$1.4B
Q3 24
$1.8B
$726.5M
Q2 24
$1.8B
$775.9M
Q1 24
$1.8B
$557.8M
Debt / Equity
HWBK
HWBK
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HWBK
HWBK
RXRX
RXRX
Operating Cash FlowLast quarter
$26.9M
$-46.1M
Free Cash FlowOCF − Capex
$22.8M
$-47.3M
FCF MarginFCF / Revenue
107.9%
-133.1%
Capex IntensityCapex / Revenue
19.3%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$32.7M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HWBK
HWBK
RXRX
RXRX
Q4 25
$26.9M
$-46.1M
Q3 25
$288.0K
$-117.4M
Q2 25
$5.8M
$-76.4M
Q1 25
$5.7M
$-132.0M
Q4 24
$25.6M
$-115.4M
Q3 24
$9.1M
$-59.2M
Q2 24
$8.9M
$-82.2M
Q1 24
$5.6M
$-102.3M
Free Cash Flow
HWBK
HWBK
RXRX
RXRX
Q4 25
$22.8M
$-47.3M
Q3 25
$-734.0K
$-117.6M
Q2 25
$5.1M
$-79.6M
Q1 25
$5.5M
$-133.8M
Q4 24
$22.6M
$-116.7M
Q3 24
$8.1M
$-63.8M
Q2 24
$8.4M
$-83.4M
Q1 24
$5.1M
$-109.0M
FCF Margin
HWBK
HWBK
RXRX
RXRX
Q4 25
107.9%
-133.1%
Q3 25
-3.6%
-2272.5%
Q2 25
25.9%
-413.9%
Q1 25
29.1%
-907.4%
Q4 24
119.7%
-2567.7%
Q3 24
44.9%
-244.6%
Q2 24
46.2%
-578.5%
Q1 24
28.5%
-789.9%
Capex Intensity
HWBK
HWBK
RXRX
RXRX
Q4 25
19.3%
3.5%
Q3 25
5.0%
4.7%
Q2 25
3.3%
16.4%
Q1 25
1.5%
12.4%
Q4 24
15.9%
28.6%
Q3 24
5.5%
17.5%
Q2 24
3.0%
8.2%
Q1 24
3.1%
48.2%
Cash Conversion
HWBK
HWBK
RXRX
RXRX
Q4 25
Q3 25
0.05×
Q2 25
0.94×
Q1 25
1.07×
Q4 24
Q3 24
1.99×
Q2 24
1.93×
Q1 24
1.26×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons